The common hormone disorder previously called polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) by a global medical consensus group. The change, announced this week, seeks to correct widespread misconceptions and diagnostic inaccuracies that have persisted for more than 30 years. Researchers say the new name better reflects the condition’s true metabolic and endocrine nature, which extends beyond the ovaries.

Experts from the International Hormone Society and the Endocrine Society led the push for the rebrand, citing evidence that PCOS affects multiple endocrine systems, not just the reproductive organs. The condition is now recognized as a systemic metabolic disorder linked to insulin resistance, cardiovascular risks, and Type 2 diabetes. The renaming follows years of criticism that the old label—focused on physical ovarian features—misled patients and doctors about its broader health impacts.

Why the name change matters for patients and doctors

The rebrand comes amid growing calls from patient advocacy groups for clearer terminology. Many women with PCOS report feeling dismissed by healthcare providers who focused only on ovarian cysts while ignoring metabolic symptoms like fatigue, weight gain, and blood sugar issues. The new term PMOS emphasizes the condition’s complex hormonal and metabolic profile, which includes elevated androgen levels and insulin dysfunction. Researchers hope this shift will lead to earlier diagnosis and more comprehensive treatment plans.

Historical records show the term PCOS was introduced in 1935 by two physicians, Irving Stein and Michael Leventhal, who linked ovarian cysts with hormonal imbalances. Over time, the diagnosis expanded to include symptoms like irregular periods and acne, but the name remained tied to the ovaries. Studies in recent decades have shown that only about 60% of women diagnosed with PCOS actually have visible cysts, highlighting the name’s inaccuracy.

What the new name means for diagnosis and treatment

The World Health Organization (WHO) is reviewing the name change and is expected to issue updated diagnostic guidelines by 2025. Until then, physicians are encouraged to use PMOS in patient records and clinical discussions. The shift aligns with similar rebranding efforts in medicine, such as renaming fibromyalgia syndrome to nociplastic pain syndrome to better describe its neurological basis.

Patient support organizations are welcoming the change. The PCOS Awareness Association has already updated its materials to reflect PMOS and is urging doctors to adopt the new terminology in medical coding and insurance claims. Early adopters include several major U.S. health systems and university hospitals in Europe, which have begun using PMOS in patient portals and research publications.

A broader shift in women’s health terminology

The PMOS rebrand reflects a growing trend in medical nomenclature to prioritize accuracy over tradition. Similar debates are underway for conditions like endometriosis, which some advocate renaming to highlight its systemic inflammatory nature. The move also responds to criticisms that outdated terms contribute to stigma and delayed care, particularly among women of color who are disproportionately misdiagnosed.

For now, the medical community is focused on education. The Endocrine Society has launched a global campaign to inform doctors, patients, and insurers about the change. While the name shift will not alter treatment protocols immediately, researchers hope it will improve awareness and lead to more personalized care strategies for the estimated 1 in 10 women worldwide affected by the condition.

What You Need to Know

  • Source: ScienceAlert
  • Published: May 16, 2026 at 11:00 UTC
  • Category: Science
  • Topics: #science · #biology · #chemistry · #becomes · #crystal · #and-more

Read the Full Story

This is a curated summary. For the complete article, original data, quotes and full analysis:

Read the full story on ScienceAlert →

All reporting rights belong to the respective author(s) at ScienceAlert. GlobalBR News summarizes publicly available content to help readers discover the most relevant global news.

Curated by GlobalBR News · May 16, 2026

🇧🇷 Resumo em Português

O Brasil, que lidera pesquisas globais sobre saúde feminina, acaba de ganhar um novo capítulo na discussão sobre saúde hormonal: a síndrome dos ovários policísticos (PCOS), agora rebatizada como síndrome ovariana metabólica e endócrina (PMOS), após décadas de confusão e diagnósticos equivocados. A mudança, anunciada por especialistas internacionais, reflete não apenas uma atualização terminológica, mas a urgência de desmistificar uma condição que afeta milhões de brasileiras — muitas delas sem saber sequer que têm o problema.

A decisão de renomear a PCOS para PMOS chega em um momento crítico para o país, onde cerca de 15% das mulheres em idade reprodutiva convivem com sintomas como irregularidade menstrual, infertilidade e resistência à insulina, frequentemente subdiagnosticados ou tratados de forma inadequada. A nova nomenclatura, que destaca a dimensão metabólica e endócrina da condição, busca esclarecer médicos e pacientes sobre os riscos associados — como diabetes tipo 2 e doenças cardiovasculares — e promover abordagens mais precisas no SUS e na rede privada. Para as brasileiras, isso pode significar diagnósticos mais rápidos e tratamentos direcionados, especialmente em um cenário onde a obesidade e o sedentarismo agravam os casos.

Agora, a expectativa é que sociedades médicas brasileiras, como a Federação Brasileira das Associações de Ginecologia e Obstetrícia (Febrasgo), adotem a nova nomenclatura nos protocolos clínicos, unificando critérios e reduzindo a subnotificação que mascara a real prevalência da doença no país.

🇪🇸 Resumen en Español

El síndrome de ovario poliquístico (PCOS), una de las alteraciones hormonales más comunes en mujeres en edad reproductiva, ha sido rebautizado como síndrome ovárico metabólico-endocrino (PMOS) tras décadas de confusión diagnóstica y estigmatización. La decisión, respaldada por la comunidad científica internacional, busca corregir décadas de estereotipos y errores médicos que han minimizado su impacto en la salud metabólica y reproductiva de millones de personas.

La nueva denominación refleja la comprensión actual de que este trastorno va más allá de los ovarios, vinculándose estrechamente con resistencia a la insulina, diabetes tipo 2 y riesgos cardiovasculares. Para los hispanohablantes, este cambio tiene implicaciones prácticas: desde una mejor atención médica hasta mayor conciencia social sobre una condición que afecta a entre un 6% y un 20% de las mujeres en la región, muchas de ellas aún sin diagnóstico preciso. Además, la revisión terminológica podría impulsar investigaciones más precisas en países de habla hispana, donde el acceso a endocrinólogos y ginecólogos especializados sigue siendo limitado.